Source comparison
MK-677 Alternatives 2026: Research Compound Comparison
CJC-1295/Ipamorelin GHRH + GHRP-2 dual agonist 6–8 days (CJC) / 2 hours (Ipa) Pulsatile, mimics physiological secretion 2–3x weekly Low. Intermittent receptor activation Best alternative for researchers prioritizing natural GH rhythm preservation and long-term
This comparison does not assign a generated winner or score.
- CJC-1295/Ipamorelin
- GHRH + GHRP-2 dual agonist
- 6–8 days (CJC) / 2 hours (Ipa)
- Pulsatile, mimics physiological secretion
- 2–3x weekly
- Low. Intermittent receptor activation
- Best alternative for researchers prioritizing natural GH rhythm preservation and long-term protocol viability
- Hexarelin
- Selective GHS-R1a agonist
- 70 minutes
- Sharp pulse, rapid clearance
- 2–3x daily
- Moderate. Manageable with dosing breaks
- Optimal for studies requiring precise timing of GH peaks relative to exercise or nutrient intake
- Thymalin
- Thymic peptide, indirect IGF-1 upregulation
- 4–6 hours
- No direct GH pulse, enhances tissue responsiveness
- 10-day cycles with 20-day washout
- None. Non-receptor-mediated mechanism
- Ideal for immune optimization studies where GH sensitivity restoration matters more than peak GH elevation
- MK-677 (reference)
- Non-peptide ghrelin agonist
- 24 hours
- Continuous baseline elevation
- Once daily
- High. 40% subjects show attenuation by week 16
- Reference standard for continuous GH elevation, but desensitization limits long-term research utility